Who are Aprepitant+Tropisetron's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Aprepitant plus Ondansetron.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/aprepitant-tropisetron.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Aprepitant+Tropisetron — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Aprepitant+Tropisetron (Aprepitant+Tropisetron) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: NK1 receptor antagonist + 5-HT3 receptor antagonist combination. Area: Oncology / Supportive Care.

phase 3 NK1 receptor antagonist + 5-HT3 receptor antagonist combination NK1 receptor (aprepitant); 5-HT3 receptor (tropisetron) Oncology / Supportive Care Small molecule Live · refreshed every 30 min

Target snapshot

Aprepitant+Tropisetron (Aprepitant+Tropisetron) — Sun Yat-sen University. Aprepitant blocks neurokinin-1 (NK1) receptors while tropisetron blocks 5-HT3 receptors, together preventing chemotherapy-induced nausea and vomiting through dual antiemetic pathways.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Aprepitant+Tropisetron TARGET	Aprepitant+Tropisetron	Sun Yat-sen University	phase 3	NK1 receptor antagonist + 5-HT3 receptor antagonist combination	NK1 receptor (aprepitant); 5-HT3 receptor (tropisetron)
Aprepitant plus Ondansetron	Aprepitant plus Ondansetron	University of Pittsburgh	marketed	NK1 receptor antagonist + 5-HT3 receptor antagonist combination	NK1 receptor (aprepitant); 5-HT3 receptor (ondansetron)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (NK1 receptor antagonist + 5-HT3 receptor antagonist combination class)

Sun Yat-sen University · 1 drug in this class
University of Pittsburgh · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Aprepitant+Tropisetron — Competitive Intelligence Brief. https://druglandscape.com/ci/aprepitant-tropisetron. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing